Investor Centre

Highlights: 

• A$7.2m being raised in an oversubscribed placement to institutional and sophisticated investors
• Strong support from existing major shareholders together with new institutional shareholders joining the register
• Strong pro-forma cash balance post raising  
• Strengthened balance sheet to support next phase of clinical trials in bone cancer, liver cancer and wound and burns scarring  
• Issue price of A$0.105 represents a 12.0% discount to the 5-day VWAP of $0.119
• Share purchase plan to raise approximately $2.0 million to eligible shareholders